The FDA postponed from Jan. 30 to April 30 its expected decision on Raptor Pharmaceutical's cystinosis drug Procysbi, a delayed-release version of cysteamine. The agency did not ask for more studies. The FDA is expected to approve Procysbi, but it has yet to decide on orphan-drug exclusivity, an analyst said.

Related Summaries